For virologically suppressed adult patients with HIV-1. See Full Indication.

JULUCA | Peer-to-Peer Video

Dr. Benjamin Young, MD, PhD, Senior Global Medical Director for ViiV Healthcare, shares 100-week data from the SWORD 1 & 2 trials for JULUCA—a complete, dolutegravir-based, 2-drug regimen for virologically suppressed (HIV-1 RNA <50 copies/mL on a stable antiretroviral therapy for at least 6 months) adult patients with HIV. In this video, Dr. Young presents the efficacy and safety results for JULUCA in virologically suppressed patients at the 48-week primary endpoint and through Week 100. The SWORD 1 & 2 trials evaluated the efficacy and safety of JULUCA in treatment-experienced adults who were virologically suppressed. Both studies were identically designed Phase 3, randomized, multicenter, open-label, parallel group, noninferiority studies with 1,024 patients combined.

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/viiv/julucahcp/10953893-100-week-p2p.mp4

You may also be interested in

CLINICAL TRIALS

Read more »

RISKS & SIDE EFFECTS

Read more »

PATIENT SUPPORT

Read more »